Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Diabetes and obesity treatment based on dual incretin receptor activation: 'twincretins'

Publikation: Bidrag til tidsskriftReviewForskningpeer review

DOI

  1. NT-proBNP predicts the cardio-renal response to aliskiren in patients with type 2 diabetes at high renal and cardiovascular risk

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Effects of liraglutide on gallbladder emptying: a randomised, placebo-controlled trial in adults with overweight or obesity

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Antibiotic exposure in early life and childhood overweight and obesity: A systematic review and meta-analysis

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. GIP and GLP-1 Receptor Antagonism During a Meal in Healthy Individuals

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. GIP's effect on bone metabolism is reduced by the selective GIP receptor antagonist GIP(3-30)NH2

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Vis graf over relationer

The gut incretin hormones glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) are secreted after meal ingestion and work in concert to promote postprandial insulin secretion and regulate glucagon secretion. GLP-1 also slows gastric emptying and suppresses appetite, whereas GIP seems to affect lipid metabolism. The introduction of selective GLP-1 receptor (GLP-1R) agonists for the treatment of type 2 diabetes and obesity has increased the scientific and clinical interest in incretins. Combining the body weight-lowering and glucose-lowering effects of GLP-1 with a more potent improvement of β cell function through additional GIP action could potentially offer a more effective treatment of diabetes and obesity, with fewer adverse effects than selective GLP-1R agonists; therefore, new drugs designed to co-activate both the GIP receptor (GIPR) and the GLP-1R simultaneously are under development. In the present review, we address advances in the field of GIPR and GLP-1R co-agonism and review in vitro studies, animal studies and human trials involving co-administration of the two incretins, as well as results from a recently developed GIPR/GLP-1R co-agonist, and highlight promising areas and challenges within the field of incretin dual agonists.

OriginalsprogEngelsk
TidsskriftDiabetes, Obesity and Metabolism Online
Vol/bind18
Udgave nummer9
Sider (fra-til)847-54
Antal sider8
ISSN1463-1326
DOI
StatusUdgivet - sep. 2016

ID: 49916929